Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$181.53
+1.9%
$171.07
$125.70
$183.04
$8.33B0.721.32 million shs2.59 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$60.42
-1.0%
$51.12
$22.28
$67.74
$24.20B1.057.10 million shs11.69 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
+0.62%+3.88%+5.51%+7.44%+42.54%
Moderna, Inc. stock logo
MRNA
Moderna
+2.78%+10.11%+30.12%+13.93%+137.63%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$181.53
+1.9%
$171.07
$125.70
$183.04
$8.33B0.721.32 million shs2.59 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$60.42
-1.0%
$51.12
$22.28
$67.74
$24.20B1.057.10 million shs11.69 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
+0.62%+3.88%+5.51%+7.44%+42.54%
Moderna, Inc. stock logo
MRNA
Moderna
+2.78%+10.11%+30.12%+13.93%+137.63%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
2.73
Moderate Buy$181.53N/A
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$36.60-39.42% Downside

Current Analyst Ratings Breakdown

Latest MRNA and IBB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
5/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
4/2/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$25.00 ➝ $48.00
(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B12.33N/AN/A$22.14 per share2.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)

Latest MRNA and IBB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.410.23%N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest MRNA and IBB Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/12/2026
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
Quarterly$0.02380.06%6/15/20266/15/20266/18/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35

Institutional Ownership

CompanyInstitutional Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A46.80 millionN/AOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable

Recent News About These Companies

Moderna: Flu Vaccine Progress Is Only Part Of The Story
Barclays Sticks to Its Hold Rating for Moderna (MRNA)
Moderna (MRNA) Rises As Market Takes a Dip: Key Facts
Moderna: The Comeback Is Now In Full Swing
Moderna snaps after six-session winning streak
FDA panel backs 1st mRNA flu vaccine
Should You Buy Moderna Before Aug. 5?
Moderna’s mRNA flu vaccine passes FDA AdCom, review underway
Moderna, Inc. $MRNA Shares Sold by Tobam
Promising Biotech Stocks To Follow Today - June 19th
FDA panel supports first mRNA-based flu vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iShares Biotechnology ETF stock logo

iShares Biotechnology ETF NASDAQ:IBB

$181.53 +3.44 (+1.93%)
As of 04:00 PM Eastern

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.

Moderna stock logo

Moderna NASDAQ:MRNA

$60.42 -0.58 (-0.95%)
Closing price 04:00 PM Eastern
Extended Trading
$60.45 +0.03 (+0.04%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.